235 Studies Now Enrolling
Menu
Search
Displaying 1 - 10 of 10
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-…
Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Closed
This is a 60-month adaptive to evaluate three siplizumab-based treatment regimens in kidney transplant recipients. The purpose of this research study is to see if the anti-rejection medications that patients normally take after transplant can be reduced or stopped completely by using several…
Condition: Transplant / Kidney Transplant
Investigator: Elizabeth Verna, MD
Status: Closed
Kidney transplant extends life, improves quality of life, and reduces healthcare costs. Unfortunately, there are not enough donated kidneys, so many people who need a transplant spend years on the waiting list. Kidneys from organ donors who have hepatitis C virus (HCV) are often thrown away, but…
Condition: Transplant / Kidney Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This purpose of this study is to understand the interaction between two different medications, tacrolimus and Paxlovid (nirmatrelvir/ritonavir), in patients who have had a kidney transplant and are being treated by their doctor for COVID-19 infection. Tacrolimus is an oral medication that is used standardly in kidney…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Closed
The purpose of this study is to determine if an investigational drug called tegoprubart (also known as AT1501) is safe and effective in preventing rejection in patients who are undergoing a kidney transplant for the first time. Participants will be randomly assigned to tegoprubart or standard treatment with tacrolimusat the…
Condition: Transplant / Kidney Transplant
Investigator: Mark Hardy, MD
Status: Closed
Subjects who undergo a kidney transplant require long term use of anti-rejection (immunosuppressive)drugs to prevent their body's immune system from attacking and damaging the newly transplanted kidney (rejection).The purpose of this study is to evaluate benefits and risks of two combinations(…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Closed
The purpose of this research study is to see if an investigational drug, BB3, is safe and effective forincreasing the amount of urine that a transplanted kidney will produce. An investigational drugis one that is not approved by the United States Food and Drug Administration (FDA). BB3 is agrowth factor-like drug, which means…
Condition: Transplant / Kidney Transplant
Investigator: Thomas Nickolas, MD, MS
Status: Closed
Kidney transplant patients are at a higher risk for bone fractures compared to the general population. We are doing a clinical trial to examine the effects of 12-months of treatment with denosumab, a monoclonal antibody against RANKL, on bone density and strength as determined by bone imaging and by non-invasive measures of…
Condition: COVID-19 (Coronavirus)
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The purpose of this study is to evaluate the safety, immune response, and efficacy of the Moderna mRNA-1273 SARS-CoV-2 vaccine in solid organ transplant recipients and healthy controls. Adult kidney and liver transplant recipients and healthy control participants who are at least 18 years of age…
Condition: COVID-19 (Coronavirus)
Investigator: Philip De Jager, PhD
Status: Closed
We need your help today to gather information about the experience of multiple sclerosis (MS) patients and the general population during the COVID-19 pandemic. Most MS patients take one of over a dozen of medications to control their disease, and these medications alter the immune system. These effects are not as strong as those experienced by patients with…